| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 23025 |
| Drug | Tezepelumab |
| Brand | Tezspire® |
| Indication | Tezepelumab (Tezspire®) is indicated as add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma, who are inadequately controlled despite high-dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment. |
| Assessment Process | |
| Rapid review commissioned | 10/05/2023 |
| Rapid review completed | 15/06/2023 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that tezepelumab not be considered for reimbursement at the submitted price*. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/02/2024 |
| Pre-submission consultation with Applicant | 05/03/2024 |
| Full submission received from Applicant | 04/06/2024 |
| Preliminary review sent to Applicant | 13/03/2025 |
| NCPE assessment re-commenced | 11/04/2025 |
| Factual accuracy sent to Applicant | 11/06/2025 |
| NCPE assessment re-commenced | 17/06/2025 |
| NCPE assessment completed | 01/07/2025 |
| NCPE assessment outcome | The NCPE recommends that tezepelumab (Tezspire®) not be considered for reimbursement as add-on treatment for adults and adolescents 12 years and older with severe asthma with blood eosinophil levels < 300 cells per microlitre, who are inadequately controlled despite high-dose inhaled corticosteroids plus another maintenance treatment (subpopulation of the licensed population)*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.